Mono- and dihydroxylated metabolites of thalidomide: Synthesis and TNF-α production-inhibitory activity

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 12, 2006, Pages 1709-1714

  Nakamura, Takanori ^a   Noguchi, Tomomi ^a   Kobayashi, Hisayoshi ^a   Miyachi, Hiroyuki ^a   Hashimoto, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hydroxythalidomide; Metabolite; Thalidomide; Tumor necrosis factor (TNF) modulator

Indexed keywords

4 HYDROXYTHALIDOMIDE; 4 N DIHYDROXYTHALIDOMIDE; 5 HYDROXYTHALIDOMIDE; 5 N DIHYDROXYTHALIDOMIDE; 5' HYDROXYTHALIDOMIDE; 5,5' DIHYDROXYTHALIDOMIDE; DRUG METABOLITE; N HYDROXYTHALIDOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MOLECULAR STRUCTURE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845432159     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.1709     Document Type: Article

References (29)

1. Bartlett J. B., Dredge K., Dalglish A. G., Nat. Rev. Cancer, 4, 314-322 (2004).
2. Bartlett J. B., Tozer A., Stirling D., Zeldis J. B., British J. Cancer, 93, 613-619 (2005).
3. Hashimoto Y., Bioorg. Med. Chem., 10, 461-479 (2002).
4. Hashimoto Y., Curr. Med. Chem., 5, 163-178 (1998).
5. Hashimoto Y., Tanatani A., Nagasawa K., Miyachi H., Drugs Future, 29, 383-391 (2004).
6. Inatsuki S., Noguchi T., Miyachi H., Oda S., Iguchi T., Kizaki M., Hashimoto Y., Kobayashi H., Bioorg. Med. Chem. Lett., 15, 321-325 (2005).
7. Noguchi T., Shinji C., Kobayashi H., Makishima M., Miyachi H., Hashimoto Y., Biol. Pharm. Bull., 28, 563-564 (2005).
8. Noguchi T., Miyachi H., Katayama R., Naito M., Hashimoto Y., Bioorg. Med. Chem. Lett., 15, 3212-3215 (2005).
9. Noguchi T., Fujimoto H., Sano H., Miyajima A., Miyachi H., Hashimoto Y., Bioorg. Med. Chem. Lett., 15, 5509-5513 (2005).
10. Lu J., Hesby N., Palmer B. D., Tingle M., Baguley B. C., Ketstell P., Ching L.-M., J. Pharm. Exp. Ther., 310, 571-577 (2004).
11. Lu J., Palmer B. D., Kestell P., Browett P., Baguley B. C., Muller G., Ching L.-M., Clin. Cancer Res., 9, 1680-1688 (2003).
12. Marks M. G., Shi J., Fry M. O., Xiao Z., Trzyna M., Pokala V., Ihnat M. A., Li P.-K., Biol. Pharm. Bull., 25, 597-604 (2002).
13. Robin S., Zhu J., Galons H., Pham-Huy C., Vlaude J. R., Tomas A., Viossat B., Tetrahedron Assym., 6, 1249-1252 (1995).
14. Teubert U., Zwingenberger K., Wnendt S., Eger K., Arch. Pharm., 331, 7-12 (1998).
15. Luzzio F. A., Duveau D. Y., Lepper E. R., Figg W. D., J. Org. Chem., 70, 10117-10120 (2005).
16. Doi M., Ijiri Y., Akagi M., Uenishi M., Urata H., Anal. Sci., 19, x51-x52 (2003).
17. Meyring M., Muehlbacher J., Messer K., Kastner-Pustet N., Bringmann G., Mannschreck A., Blaschke G., Anal. Chem., 74, 3726-3735 (2002).
18. Scott M. C., Todd P. H., Milton L. B., Org. Lett., 5, 2865-2867 (2003).
19. Fukushima H., Hiratake A., Takahashi M., Saito M., Munetomo E., Kitano K., Saito H., Takaoka Y., Yamamoto K., Bioorg. Med. Chem., 12, 6053-6061 (2004).
20. Xiaojun Z., Aaron C. S., Wen J., Tetrahedron Lett., 42, 5335-5338 (2001).
21. Hara S., Makino K., Hamada Y., Tetrahedron, 60, 8031-8035 (2004).
22. Claire M. M., Douglas W. Y., J. Chem. Soc., Perkin Trans. 1, 23, 3519-3530 (1997).
23. Florine C., Christine E., Tetrahedron Lett., 37, 5131-5134 (1996).
24. Wallach D., Cytokine Growth Factor Rev., 7, 211-221 (1996).
25. Pasparakis M., Alexopoulou L., Douni E., Kollias G., Cytokine Growth Factor Rev., 7, 223-229 (1996).
26. Makonlawkeyoon S., Limson-Pombre R. N. R., Moreira A. L., Schauf V., Kaplan G., Proc. Natl. Acad. Sci. U.S.A., 90, 5974-5978 (1993).
27. Kaplan G., Immunobiology, 191, 564-568 (1994).
28. Shibata Y., Sasaki K., Hashimoto Y., Iwasaki S., Chem. Pharm. Bull., 44, 156-162 (1996).
29. Miyachi H., Ogasawara A., Azuma A., Hashimoto Y., Bioorg. Med. Chem., 5, 2095-2102 (1997).